PUBLICATIONS
Acuitas Scientists, in Collaboration With Other Researchers, Have Published Extensively on LNP Development and Characterization.
KEY PUBLICATIONS
Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy. DOI: 10.1016/j.omtn.2024.102175
Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” Proceedings of the National Academy of Sciences of the United States of America. DOI: 10.1073/pnas.2319856121
Matias et al. (2024) “mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis” Scientific Reports. DOI: 10.1038/s41598-023-50389-6
Birdsall et al. (2024) “Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs” Journal of Chromatography B. DOI: 10.1016/j.jchromb.2024.124005
Kunkeaw et al. (2023) “A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax” NPJ Vaccines. DOI: 10.1038/s41541-023-00786-9
Breda et al. (2023) “In vivo hematopoietic stem cell modification by mRNA delivery” Science. DOI: 10.1126/science.ade6967
Hoffmann et al. (2023) “ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines” Cell. DOI: 10.1016/j.cell.2023.04.024
Connors et al. (2023) “Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals” Nature. DOI: 10.1038/s42003-023-04555-1
Schiepers et al. (2023) “Molecular fate-mapping of serum antibody responses to repeat immunization” Nature. DOI: 10.1038/s41586-023-05715-3
Arevalo et al. (2022) “A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes” Science. DOI: 10.1126/science.abm0271
Pardi et al. (2022) “Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses” Nature. DOI: 10.1038/s41467-022-32149-8
Gorsuch et al. (2022) “Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo” Molecular Therapy. DOI: 10.1016/j.ymthe.2022.05.013
Mu et al. (2022) “mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice” Cell Reports. DOI: 10.1016/j.celrep.2022.110514
Rurik et al. (2022) “CAR T cells produced in vivo to treat cardiac injury” Science. DOI: 10.1126/science.abm0594
Mallory et al. (2021) “Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice” NPJ Vaccines. DOI: 10.1038/s41541-021-00345-0
Rothgangl et al. (2021) “In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels” Nat Biotech. DOI:10.1038/s41587-021-00933-4
Musunuru et al. (2021) “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” Nature. DOI:10.1038/s41586-021-03534-y
Rizvi et al. (2021) “Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA” Nat Commun. DOI:10.1038/s41467-021-20903-3
Villiger et al. (2021) “In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA” Nat Biomed Eng. DOI:10.1038/s41551-020-00671-z
Weissman et al. (2020) “D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization” Cell Host Microbe. DOI:10.1016/j.chom.2020.11.012
Lederer et al. (2020) “SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation” Immunity. DOI:10.1016/j.immuni.2020.11.009
Laczkó et al. (2020) “A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice” Immunity. DOI:10.1016/j.immuni.2020.07.019
McKay et al. (2020) “Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice” Nature Communications. DOI:10.1038/s41467-020-17409-9
Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy. DOI:10.1016/j.ymthe.2020.04.018
Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature. DOI:10.1038/s41586-020-2220-1
Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” Proc Natl Acad Sci U S A. DOI: 10.1073/pnas.1912012117
Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Sci Transl Med. DOI: 10.1126/scitranslmed.aav5701
Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Mol Ther.Nucleic Acids. DOI: 10.1016/j.omtn.2019.08.001
Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Mol Ther.Nucleic Acids. DOI: 10.1016/j.omtn.2019.03.003
Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Mol Ther. DOI: 10.1016/j.ymthe.2019.03.003
Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” J Control Release. DOI:10.1016/j.jconrel.2018.10.015
Pardi et al. (2018b) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies” Nature Communications. DOI:10.1038/s41467-018-05482-0
Pardi et al. (2018a) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine. DOI:10.1084/jem.20171450
Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines. DOI:10.1038/s41541-017-0032-6
Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine. DOI:10.15252/emmm.201707678
Pardi et al. (2017b) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications. DOI:10.1038/ncomms14630
Pardi et al. (2017a) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature. DOI:10.1038/nature21428
Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” J Controlled Release. DOI:10.1016/j.jconrel.2015.08.007
Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Mol Ther. DOI:10.1038/mt.2015.103
Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Mol Ther Nucleic Acids. DOI:10.1038/mtna.2013.66
Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Mol Ther. DOI:10.1038/mt.2013.124
Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angew Chem Int Ed Engl. DOI:10.1002/anie.201203263
Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nat Biotechnol. DOI:10.1038/nbt.1602
Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Mol Ther. DOI:10.1038/mt.2010.85